Company / SG&A Expense
Traws Pharma, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.3M
FY2024
5-year range
$8.3M / $12.3M
FY2020-FY2024
Trend
+45.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $7M in FY2018 to $15M in FY2015.
Based on SEC 10-K filings.
$12M in FY2024 with a 5-year CAGR of +10.1%.
Increased from $9M to $12M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.1%, indicating consistent growth.
- In FY2024, sg&a expense increased 45.5% year-over-year.
- Peak sg&a expense was recorded in FY2015.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -42.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.3M | +45.5% |
| FY2023 | $8.4M | -10.4% |
| FY2022 | $9.4M | +13.2% |
| FY2021 | $8.3M | -0.2% |
| FY2020 | $8.3M | +10.0% |
| FY2019 | $7.6M | +2.4% |
| FY2018 | $7.4M | -19.3% |
| FY2017 | $9.2M | -3.7% |
| FY2016 | $9.5M | -36.9% |
| FY2015 | $15.1M | -3.7% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026